Technology
7 min read
ValGenesis Platform to Digitalize Vaccine Manufacturer's Validation Processes
Business Wire
January 20, 2026•2 days ago

AI-Generated SummaryAuto-generated
A leading vaccine manufacturer will utilize the ValGenesis platform to digitalize equipment qualification and computer system validation. This phased implementation aims to transition from paper-based processes to a digital framework, enhancing efficiency, traceability, and compliance with stringent regulatory expectations in vaccine production. The initiative will standardize validation execution across manufacturing operations and sites.
SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis Inc., the global leader in digital validation lifecycle management, today announced that a leading vaccine manufacturer will use its platform to digitalize and standardize equipment qualification and computer system validation (CSV) across regulated manufacturing operations.
The ValGenesis solution is well suited to support complex qualification and validation activities in highly regulated, high-throughput vaccine manufacturing environments.
Share
The manufacturer selected ValGenesis to support the stringent regulatory expectations inherent to vaccine production — including data integrity, traceability, and audit readiness — while enabling scalable, standardized validation execution across both equipment and control systems. The ValGenesis solution is well suited to support complex qualification and validation activities in highly regulated, high-throughput vaccine manufacturing environments.
The implementation will follow a three-phase rollout. Phase 1 will focus on digitizing equipment qualification and validating associated control systems that support vaccine-manufacturing operations. Phase 2 will expand the use of ValGenesis to include broader, application-level computer system validation. Phase 3 will extend both capabilities to an additional manufacturing site, further strengthening standardization across the organization.
Through this initiative, the vaccine manufacturer aims to transition from paper-based validation processes to a structured, digital validation framework that improves execution efficiency, strengthens end-to-end traceability, and supports consistent compliance with global regulatory requirements. ValGenesis will provide a unified system to manage qualification and validation activities across the vaccine manufacturing lifecycle.
“Vaccine manufacturers operate under some of the most demanding regulatory and quality expectations in the industry,” said Steve Reynolds, chief revenue officer at ValGenesis. “By adopting a phased, digital approach to equipment qualification and computer system validation, this customer is strengthening its validation foundation while enabling greater consistency, scalability, and inspection readiness across sites.”
About ValGenesis Inc.
Rate this article
Login to rate this article
Comments
Please login to comment
No comments yet. Be the first to comment!
